



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: UCHIDA9

In re Application of:

IA No: PCT/JP2004/000291

IA Filed: January 16, 2004

Appln. No.: 10/542,577

Washington, D.C.

For: HEMOSTATIC MATERIAL

October 18, 2005

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop Amendment
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- [X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:
- [X] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.
- [X] B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114; or

- [X] 2.In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.
- [X] 3. Document(s) AB, AC, AD, and AE are not in the English language. In accordance with 37 CFR §1.98(a)(3), Applicant states:
 - [X] An English translation of each document AB, AC, and AE, (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.
 - [X] For documents <u>AD</u>, a corresponding Englishlanguage patent or published application is included on the accompanying Form BN/SB/08A, with a line drawn in the margin connecting the non-English-language document with its corresponding English-language document.
 - [X] A concise explanation of the relevance of document(s) AB, AC, and AE is found in the attached <u>International</u> search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).
 - [] A concise explanation of the relevance of document(s) is set forth as follows:
 - [X] A concise explanation of the relevance of document(s) \underline{AD} can be found on page $\underline{4}$ of the specification.
 - [] A concise explanation of the relevance of document(s) ____ can be found on the attached sheet.

- [X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK

Attorneys for Applicant (s)

By:

Sheridan Neimark

Registration No. 20,520

SN:srd

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197 Facsimile: (202)737-3528

G:\BN\A\Aoyb\Uchida9\pto\IDS 18 OCT 05.doc

| Substitute for form 1449A/PTO | | | | Complete if Known | |
|---|---------------------|----------|-----------|------------------------|-------------------------|
| | | | | Application Number | 10/542,577 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | CLOSURE | Filing Date | |
| | | | PLICANT | First Named Inventor | Takanori UCHIDA, et al. |
| • | | <i>,</i> | | Group Art Unit | |
| | (use as many sheets | as n | ecessary) | Examiner Name | |
| Sheet | 1 | of | 1 | Attorney Docket Number | UCHIDA9 |

| | | | U.S. PAT | ENT DOCUMENTS | |
|-----------------------|--------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No.1 | Document Number Number-Kind Code ^{2 (if known)} | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | US-4,453,939 | 06-12-1984 | ZIMMERMAN, et al. | |
| | | US- | | | |
| | | US- | | | |
| | | US- | , | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| <u> </u> | | US- | | | <u></u> |
| | | US- | | | |
| | | US- | • | | |
| | | US- | • | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

| | FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------|--------------------------|--|-----------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | AB | JP 2002-315819 A | 10-29-2002 | TAKIRON CO LTD | | Abs |
| | AC | JP 5-76586 A | 03-30-1993 | GUNZE LTD | | Abs |
| | AD | JP 61-34830 B2 | 08-09-1986 | | | |
| | AE | WO 00/38752 A1 | 07-06-2000 | CENTEON PHARMA GMBH | | Abs |
| | AF | WO 02/058749 A2 | 08-01-2002 | NY-COMED PHARMA AS | | |

| | OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | | |
|-----------------------|---|--|----------------|--|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² | | |
| | | | | | |
| | | • | | | |
| | | | | | |
| | | | | | |

| Examiner | Date |
|-----------|------------|
| Signature | Considered |

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.